公开(公告)号：EP1684754A1

公开(公告)日：2006-08-02

申请号：EP04811719.6

申请日：2004-11-19

申请人： Bristol-Myers Squibb Company

发明人： O'CONNOR, Stephen P. ,  ROBL, Jeffrey ,  AHMAD, Saleem ,  BISAHA, Sharon ,  MURUGESAN, Natesan ,  NGU, Khehyong ,  SHI, Yan ,  STEIN, Philip D. ,  SOUNDARARAJAN, Nachimuthu ,  NATALIE, Kenneth J. Jr. ,  KOLLA, Laxma R. ,  SAUSKER, Justin ,  QUINLAN, Sandra L. ,  FAN, Junying ,  PETSCH, Dejah ,  GUO, Zhenrong

IPC分类号： A61K31/435 ,  A61K31/505 ,  C07D401/14 ,  C07D471/04

CPC分类号： C07D213/80 ,  C07D211/76 ,  C07D401/14 ,  C07D471/04 ,  C07D491/04 ,  C07D498/04 ,  C07D513/04

摘要： Compounds are provided having the following structure (I) and pharmaceutically acceptable salts thereof, A is (II) or (III); wherein R1, R2, R3, R4, U, V, W, Y, and n are as defined above, which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement therapy. A method for treating the above diseases employing the above compounds is also provided.